Swiss National Bank Acquires 4,900 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Swiss National Bank boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 1.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 270,000 shares of the company’s stock after acquiring an additional 4,900 shares during the period. Swiss National Bank’s holdings in Maravai LifeSciences were worth $3,864,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Captrust Financial Advisors increased its position in Maravai LifeSciences by 1.3% during the 1st quarter. Captrust Financial Advisors now owns 33,535 shares of the company’s stock worth $1,183,000 after buying an additional 442 shares during the period. Signaturefd LLC increased its position in shares of Maravai LifeSciences by 63.2% in the fourth quarter. Signaturefd LLC now owns 1,962 shares of the company’s stock worth $28,000 after purchasing an additional 760 shares during the period. Zions Bancorporation N.A. bought a new position in shares of Maravai LifeSciences in the first quarter worth $28,000. ProShare Advisors LLC increased its position in shares of Maravai LifeSciences by 6.5% in the third quarter. ProShare Advisors LLC now owns 12,804 shares of the company’s stock worth $327,000 after purchasing an additional 785 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its stake in Maravai LifeSciences by 0.5% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 214,784 shares of the company’s stock valued at $5,483,000 after buying an additional 1,138 shares in the last quarter. Institutional investors own 48.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on MRVI. Stifel Nicolaus reduced their price objective on Maravai LifeSciences from $18.00 to $17.00 in a research note on Tuesday, May 9th. Credit Suisse Group reduced their price objective on Maravai LifeSciences from $23.00 to $18.00 in a research note on Tuesday, May 9th. Morgan Stanley cut their price target on Maravai LifeSciences from $32.00 to $29.00 and set an “overweight” rating on the stock in a research note on Friday, February 24th. Robert W. Baird cut their price target on Maravai LifeSciences from $25.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday, February 23rd. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Maravai LifeSciences from $25.00 to $23.00 in a research note on Tuesday, May 9th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Maravai LifeSciences presently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Maravai LifeSciences Trading Up 4.9 %

Shares of MRVI stock opened at $13.38 on Friday. The company has a market cap of $3.36 billion, a P/E ratio of 11.63 and a beta of -0.23. The stock has a 50 day simple moving average of $13.83 and a two-hundred day simple moving average of $14.16. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.69 and a current ratio of 6.13. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $11.89 and a fifty-two week high of $35.82.

Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last issued its earnings results on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $79.03 million during the quarter, compared to the consensus estimate of $79.72 million. Maravai LifeSciences had a return on equity of 38.41% and a net margin of 21.36%. The company’s revenue for the quarter was down 67.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.54 earnings per share. Research analysts forecast that Maravai LifeSciences Holdings, Inc. will post 0.3 earnings per share for the current year.

Maravai LifeSciences Company Profile

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.